Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study is aimed at investigation of efficacy and safety of ustekinumab (monoclonal
antibody against interleukin 12 and 23) treatment in patients with active ankylosing
spondylitis (AS) fulfilling the modified New York criteria who have had an inadequate
response to standard therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or do not
tolerate or have a contraindication for NSAIDs.